Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms

Rosa, Stefano La; Inzani, Frediano; Vanoli, Alessandro; Klersy, Catherine; Daınese, Linda; Rindi, Guido; Capella, Carlo; Bordi, Cesare; Solcia, Enrico

doi:10.1016/j.humpath.2011.01.018

Cited by 180 publications

(177 citation statements)

References 28 publications

Supporting

Mentioning

153

Contrasting

Unclassified

Order By: Relevance

“…Growth pattern of NETs can be quite different and even quite heterogeneous in the same tumour forming nests, trabecular, tubules, rosettes or solid structures of tumour cells. Immunohistochemically, gastric NETs are consistent chromogranin A positive and have by definition a low Ki67 (up to 2%) [19,20].…”

Section: Neuroendocrine Tumours (Nets)mentioning

confidence: 99%

Malignant Gastric Tumours: The Role of Pathologist in the Diagnosis and for Therapeutic Decisions

Quaas¹

2017

Gastric Cancer

View full text Add to dashboard Cite

This chapter gives an overview about the most important malignant gastric tumours from the perspective of the pathologist. The first focus is the systematic classification of gastric carcinoma, neuroendocrine tumours, mesenchymal tumours and malignant lymphoma with related histomorphology-based and molecular-based diagnosis criteria including differential diagnosis pathologists have to consider when dealing with gastric tumours. The second focus addresses the issues of personalized therapy options in gastric tumours pathologists have to bear in mind. Currently, some subtypes of gastric adenocarcinomas have been proposed with therapeutic implications like microsatellite-instable carcinoma and checkpoint-inhibition or Her2/neu positive adenocarcinoma of intestinal-type and specific tyrosine-receptor blockade. Mesenchymal tumours are rare and can morphologically be quite variable. Mucosa-associated lymphoid tissue (MALT)-related marginal zone lymphoma is the most frequent gastric lymphoma but all other B-and T-cell lymphoma can occur in the stomach as well, and an exact subcharacterisation is very important due to different treatment decisions (e.g. eradication of helicobacter-pylori in MALT-lymphoma as first choice treatment vs. chemotherapy in Burkitt-lymphoma). Pathologists have to consider a large spectrum of differential diagnosis and conflicting immunohistochemical and molecular results. It will become more and more important to find out therapeutically relevant tumour subtypes and to use biomarkers to predict a successful individualized treatment.

show abstract

Section: Neuroendocrine Tumours (Nets)mentioning

confidence: 99%

Malignant Gastric Tumours: The Role of Pathologist in the Diagnosis and for Therapeutic Decisions

Quaas¹

2017

Gastric Cancer

View full text Add to dashboard Cite

show abstract

“…They are rare or extremely rare outside the lung and can develop in virtually any location. Relatively large series were reported in the gastroenteropancreatic (GEP) area, including the esophagus [6], stomach [7,8], colon and rectum [9], and pancreas [10]. In addition, EPNECs of the small or large type were investigated in the prostate [11,12], bladder [13] and uterine cervix [14,15].…”

Section: Relevant Issues and Possible Solutions 21 Issue 0: Organ Dmentioning

confidence: 99%

Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues

et al. 2014

View full text Add to dashboard Cite

Summary Extrapulmonary neuroendocrine carcinoma (EPNEC) is a heterogeneous and rare group of high-grade neoplasms occurring in different organs. They usually share a poor prognosis, but diagnostic and therapeutic options still include several controversial issues, due to the rarity of this condition and to differences in architecture and cell size, being some cases pure small cell carcinomas, other pure large cell neuroendocrine carcinomas and some others combined/mixed neuroendocrine carcinomas with a conventional non-neuroendocrine carcinoma. In addition, the therapeutic strategy varies in different organs (surgery and/or chemotherapy and/or radiation therapy and/or targeted treatments), and clinicians and pathologists are asked to interact to reach an accurate classification of every single case, as well as the most appropriate selection of the treatment options, even considering different time points of each EPNEC natural history. This overview highlights controversial pathological and clinical issues and summarizes possible solutions to most of such EPNEC-related problems.

show abstract

“…The basic therapy in type 1 gastric NENs, whose form is usually polypoid, are endoscopic procedures, similarly to type 2 gastric NENs, which occur less frequently [49,50].…”

Section: Duodenal Neuroendocrine Tumoursmentioning

confidence: 99%

“…Gastric neuroendocrine tumours type 1 are rarely associated with distant metastases, unlike type 2 gastric NENs, in which metastases can be present in 10-30% of patients already at the moment of diagnosis [49,51]. Despite a low proliferation index, NENs G1 tend to recur, and the median recurrence-free survival is 24 months; however, the literature presents cases of transformation into NEC in 3% of patients [51].…”

Section: Duodenal Neuroendocrine Tumoursmentioning

confidence: 99%

Nowotwory neuroendokrynne żołądka i dwunastnicy z uwzględnieniem gastrinoma — zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Rydzewska

Cichocki

Ćwikła

et al. 2014

Endokrynologia Polska

View full text Add to dashboard Cite

This paper presents the updated Polish Neuroendocrine Tumour Network expert panel recommendations on the management of neuroendocrine neoplasms (NENs) of the stomach and duodenum, including gastrinoma. The recommendations discuss the epidemiology, pathogenesis and clinical presentation of these tumours as well as their diagnosis, including biochemical, histopathological and localisation diagnosis. The principles of treatment are discussed, including endoscopic, surgical, pharmacological and radionuclide treatment.

show abstract

Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms

Cited by 180 publications

References 28 publications

Malignant Gastric Tumours: The Role of Pathologist in the Diagnosis and for Therapeutic Decisions

Malignant Gastric Tumours: The Role of Pathologist in the Diagnosis and for Therapeutic Decisions

Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues

Nowotwory neuroendokrynne żołądka i dwunastnicy z uwzględnieniem gastrinoma — zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)

Contact Info

Product

Resources

About